Assyro AI

FDA Orange Book · active-ingredient family

Iothalamate sodium

Iothalamate sodium is approved in 3 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:ANGIO-CONRAY · NDA 013319

3

Brand (NDA)

0

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · injectable

ProductApplicantApplicationTEApproved
ANGIO-CONRAYMALLINCKRODTNDA 013319Approved Prior to Jan 1, 1982
CONRAY 325MALLINCKRODTNDA 017685Approved Prior to Jan 1, 1982
CONRAY 400MALLINCKRODTNDA 014295Approved Prior to Jan 1, 1982

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Iothalamate sodium — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.